Us News

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

The company announced the initial closing of an $11 million note under a previously disclosed $250 million private placement convertible note facility.

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

The offering includes 11.125 million shares of common stock priced at $24.00 per share, a 5.1% discount to Thursday’s close at $25.31.

The company said the U.S. FDA identified deficiencies that prevent labeling discussions for a drug to treat allergic reactions.

Oklo’s agreement with Meta Platforms advances its plans to develop a 1.2 GW power campus in Ohio to support Meta’s data centers.

Cemtrex has completed its acquisition of Texas-based engineering firm Invocon, establishing a new Aerospace & Defense segment.

Early signals show futures flat, SPY sentiment cooling, and tech traders turning bullish.

The updated outlook implies Ardelyx’s lead therapy could reach $1 billion in annual revenue about four years earlier than previously expected.

The move comes as the EV maker looks to revive demand in a region where sales performance has been uneven.

The development follows OpenAI’s rollout of ChatGPT Health, which helps users blend health information with AI-driven insights.

Joseph Todisco’s annual base salary increases to $750,000 from $665,000, effective Jan. 1.

The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.

Attention also centered on Trump’s comments on proposed mortgage bond purchases.

The House vote also reignited criticism from Republicans who oppose extending the subsidies.

Archer will integrate NVIDIA’s IGX Thor platform into future versions of its Midnight electric air taxi.

The company reported positive initial data from its ongoing Phase 1b clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Datavault AI said the deployment will help deliver data storage, real-time processing and scoring, tokenization, and ultra-low-latency performance.

The surge in demand is being driven by the rapid expansion of AI and data centers, core economic activity, energy transition, including EVs and renewables, and defense modernization, S&P Global reported.

The FDA cited concerns that the controlled phase advance protocols used in studies do not fully replicate real-world jet travel conditions.

The expansion adds two new right-hand drive markets to Nio’s global footprint.

Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.

Retail traders overwhelmingly picked SpaceX as their most anticipated 2026 IPO, far outpacing OpenAI and Discord.

Farley said Ford is pursuing three initiatives, all being developed internally.

Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.

Trump’s policy remarks rattled markets, pressuring defense and financial stocks.

Yartemlea shipments to wholesalers are expected in the third week of January.

The FDA’s feedback supports a planned new drug application submission in the second half of 2026.

Spot gold prices fell 1% to $4,448 an ounce, while Copper prices on the LME fell 2.8% to $12,880 per ton on Wednesday.

The wallet, built with Tether’s Wallet Development Kit, currently supports Bitcoin, Tether (USDT), and Tether Gold (XAUt).

The airline expects its fleet to exceed 550 aircraft by 2035.

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

The company highlighted ongoing FDA discussions around a potential rolling NDA submission for treatment-resistant depression, with additional Phase 3 data expected in 2026.

Jefferies downgraded the stock to ‘Hold’ from ‘Buy’ and cut its price target to $260 from $269.

Nvidia, memory-chip stocks, and AI-linked names dominated chatter ahead of data and earnings.

Mega-cap names remained in focus, with Amazon and Palantir each jumping over 3%.

The company will also launch its refreshed SUV lineup in Brussels on Friday.

With enhanced ACA subsidies now expired, average out-of-pocket premiums for Obamacare users are expected to more than double.

The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data.

Altimeter Capital’s Freda Duan said broader access to Nvidia’s full self-driving stack could change how autonomy is adopted across the industry.

The UBS call follows Novo Nordisk's announcement of U.S. pricing for its obesity pill, with monthly costs starting at $149 for lower doses.

Musk outlined Tesla’s AI hardware setup and vehicle scale, while Nvidia CEO Jensen Huang hyped up the EV maker’s autonomous driving stack.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data this week.

Nvidia CEO Jensen Huang said Alpamayo represents a turning point for physical AI in real-world autonomy.

Nio detailed its next development phase, emphasizing scaling operations and product refreshes in 2026.

The buzz around SoFi’s potential inclusion in the benchmark continues to grow, with the stock already adding 12% this year following a 70% surge in 2025.

Energy stocks outperformed, with gains across oilfield services, refiners and major producers.

Several clinical readouts and regulatory decisions are scheduled for Eli Lilly in 2026.